Aspire Biopharma Holdings, Inc. (ASBP)
| Market Cap | 21.03M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -17.02M |
| Shares Out | 48.90M |
| EPS (ttm) | -0.35 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,367,880 |
| Open | 0.5705 |
| Previous Close | 0.6024 |
| Day's Range | 0.4012 - 0.5763 |
| 52-Week Range | 0.2150 - 15.8000 |
| Beta | 0.91 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 14, 2025 |
About ASBP
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, engages in development and marketing of disruptive technology for novel sublingual delivery mechanisms in the United States. The company offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. It also develops formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In ... [Read more]
Financial Performance
Financial StatementsNews
Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025
Sublingual nano technology delivers caffeine rapidly to the blood stream, bringing its unique disruptive benefits to the Pre-workout market Initial production has commenced with six flavor options Exp...
Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
Trial marks key milestone in driving pipeline progress Phase 1 trial scheduled for completion mid-June 2025 Topline data from High-Dose Aspirin Trail anticipated early in 3Q with the potential to supp...
Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21
HUMACAO, PUERTO RICO AND NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug de...
Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
Company achieves another milestone relating to its clinical trial strategy HUMACAO, PR and NEW YORK, NY / ACCESS Newswire / April 29, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or ...
Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17
HUMACAO, PR AND NEW YORK, NY / ACCESS Newswire / April 14, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery...
Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement
Plans to conduct consumer and safety testing during second quarter 2025 Desert Stream Inc.,a leading private label manufacturer in the health and wellness industry, performing initial production Singl...
Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
One clinical trial site activated Patient enrollment expected in April Trial designed to evaluate safety, pharmacokinetics and pharmacodynamics, of Aspire's sublingual aspirin product Aspire anticipat...
Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice (“GMP”) Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin
Subsequent phase involves completion of chemistry, manufacturing, and controls (CMC) testing for data to support FDA submission Company expects to commence bioavailability study in April 2025 Aspire i...
Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform
HUMACAO, PUERTO RICO AND NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug...
An Interview with the CEO: How Aspire Biopharma is Disrupting a $100 Billion Market with Sublingual Innovation
SmallCaps Daily Dives Deep with CEO Kraig Higginson to Discuss Aspire's Mission to Enhance Efficacy and Reduce Side Effects New York, New York--(Newsfile Corp. - March 11, 2025) - Aspire Biopharma Hol...
Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement
New product expected to set a new standard for potency and performance in the estimated $20 billon pre-workout market Desert Stream Inc., a well-established nutritional and supplement manufacturer of ...
Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin
Initial feasibility study of its soluble, Ph neutral, fast acting granular or powder drug delivery system is complete Test results support the next development step with Phase 1clinical trial expected...
Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase Agreement
NEW YORK CITY, NY / ACCESS Newswire / February 20, 2025 / Aspire Biopharma, Inc. ("Aspire" or the "Company"), a developer of a multi-faceted patent-protected disruptive drug delivery mechanism technol...